Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Inclusion Criteria: * Adult women (≥ 18 years of age) with advanced TNBC. * Histological or cytological evidence of estrogen-receptor negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth factor-2 receptor negative (HER2-) Breast Cancer by local laboratory testing, based on last available tumor tissue. * ER/PgR negativity to follow local guidelines * If IHC HER2 2+, a negative FISH test is required * A pre-treatment tumor biopsy demonstrating high TAM content as assessed per the central laboratory * Patients must have: At least one measurable lesion per RECIST 1.1. (Note: Measurable lesions include lytic or mixed (lytic + blastic) bone lesions, with an identifiable soft tissue component that meets the measurability criteria) Exclusion Criteria: * Prior chemotherapy for advanced BC. Previous adjuvant/neoadjuvant chemotherapy is allowed (carboplatin, cisplatin or gemcitabine only if \> 12 months has passed since last administration). * Therapy for underlying malignancy within 2 weeks prior to start of study treatment: * Chemotherapy, biologic therapy (antibodies and biologically targeted small molecules) * Radiotherapy * Major surgery * Patients receiving concomitant immunosuppressive agents or chronic corticosteroids (≥10 mg of prednisone or equivalent) at the time of first study dose. * Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening. * Known history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection. * Patients with the following laboratory values during screening and on Day 1 predose: * Absolute Neutrophil Count (ANC) \< 1.5x109/L * Hemoglobin \< 9 g/dL * Platelets \< 100x109/L * Serum creatinine \> 1.5 x ULN * Serum total bilirubin \> 1.5 x ULN * AST/SGOT and ALT/SGPT \> 3.0 x ULN